Share

December 2016; 3 (6) ArticleOpen Access

Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder

Velina S. Chavarro, Maureen A. Mealy, Alexandra Simpson, Anna Lacheta, Florence Pache, Klemens Ruprecht, Stefan M. Gold, Friedemann Paul, Alexander Ulrich Brandt, Michael Levy
First published October 24, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000286
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1243

Share

Article Information

vol. 3 no. 6 e286
DOI: 
https://doi.org/10.1212/NXI.0000000000000286
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 10, 2016
  • Accepted in final form August 1, 2016
  • First Published October 24, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Velina S. Chavarro, AM*,
    2. Maureen A. Mealy, RN, MSCN*,
    3. Alexandra Simpson, AM,
    4. Anna Lacheta,
    5. Florence Pache, MD,
    6. Klemens Ruprecht, MD,
    7. Stefan M. Gold, PhD,
    8. Friedemann Paul, MD,
    9. Alexander Ulrich Brandt, MD‡ and
    10. Michael Levy, MD‡
  1. Velina S. Chavarro, AM*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NeuroCure Fellowship 2015-2027 by Deutsche Forschungsgemeinschaft DFG Exc 257

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Maureen A. Mealy, RN, MSCN*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria from Consortium of Multiple Sclerosis Centers

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Alexandra Simpson, AM,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Anna Lacheta,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Florence Pache, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Commercial: Travel grant from Genzyme, a Sanofi Company (2) Commercial: Travel grant from Bayer (3) Commercial: Travel grant from Biogene Idec (4) Non-profit: Travel grant from ECTRIMS ( European Committee for Treatment and Research in Multiple Sclerosis)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Klemens Ruprecht, MD,
    7. Scientific Advisory Boards:

    1. (1)sanofi-aventis/Genzyme (2)Novartis (3)Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Bayer Healthcare, travel and speaker honoraria (2)Biogen Idec, travel and speaker honoraria (3)Merck Serono, travel and speaker honoraria (4)sanofi-aventis/Genzyme, travel and speaker honoraria (5)Teva Pharmaceuticals, travel and speaker honoraria (6)Novartis, travel and speaker honoraria (7)Guthy Jackson Charitable Foundation, travel honoraria

    Editorial Boards:

    1. (1) PLOS ONE, Academic Editor, since 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Neurologie in Frage und Antwort, Elsevier, 2000-2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis

    Research Support, Government Entities:

    1. (1)German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Stefan M. Gold, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. University Hospital Hamburg-Eppendorf, Group Leader Charite Universit?tsmedizin

    Consultancies:

    1. University of California Los Angeles (non-profit) Cedars Sinai Medical Center (non-profit)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Deutsche Forschungsgemeinschaft GO1357/4-1, 5-1, 5-2, 8-1, 7-1, 9-1,PI, 2012-2018 National MS Society, RG5225A1/1, RG-1507-05418, PR-1412-02262, 2015-2020

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Friedemann Paul, MD,
    9. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune steering committee

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Alexander Ulrich Brandt, MD‡ and
    10. Scientific Advisory Boards:

    1. (1) Biogen VISION study, scientific advisory board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, funding for travel to conference (2) Bayer, speaker honoraria (3) Biogen, funding for travel to conference (4) Teva, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Pending patent application Method and System For Optic Nerve Head Shape Quantification. (2) Pending patent application Perceptive Visual Computing based Postural Control Analysis. (3) Pending patent application Multiple Sclerosis Biomarker. (4) Pending patent application Perceptive Sleep Motion Analysis

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Nexus, Hospital Information Systems (2) Motognosis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis Pharma (2) Biogen Idec

    Research Support, Government Entities:

    1. (1) BMWi, ZIM KF2443803KJ, PI, two years (2) BMWi, ZIM KF2291305AK3, Co-I, one year (3) BMWI, EXIST-FT 03EFEBE079, PI, two years (4) BMBF, NEU2 N2-ADVISIMS, Co-I, three years Stock/Stock Options, Medical Equipment & Materials: (1) Motognosis, 2014 (ongoing)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Michael Levy, MD‡
    11. Scientific Advisory Boards:

    1. Asterias, Chugai, Alexion

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board member of Multiple Sclerosis and Related Disorders

    Patents:

    1. 1. Aquaporin-4 sequence that elicits pathogenic T cell response in animal model of neuromyelitis optica. 2. Description: patent covers use of peptide for diagnostic and therapeutic developments.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Guidepoint Global; Gerson Lehrman Group; Cowen Group

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Viropharma/Shire, Acorda, ApoPharma and Sanofi, Genzyme, Alnylam, Alexion, Terumo BCT

    Research Support, Government Entities:

    1. National Institute of Neurological Diseases and Stroke

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy-Jackson Charitable Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From NeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
  1. Correspondence to Dr. Paul: friedemann.paul{at}charite.de
View Full Text

Article usage

Article usage: October 2016 to March 2023

AbstractFullPdfSource
Oct 20161225454Highwire
Nov 201616027843Highwire
Nov 201606731pmc
Dec 201626834131Highwire
Dec 201602716pmc
Jan 2017109407Highwire
Jan 201702914pmc
Feb 20174397Highwire
Feb 201701812pmc
Mar 201746132Highwire
Mar 20170197pmc
Apr 20173584Highwire
Apr 201731110pmc
May 201723244Highwire
May 201782322pmc
Jun 201727168Highwire
Jun 201791717pmc
Jul 201724193Highwire
Jul 201741213pmc
Aug 201715174Highwire
Aug 201721314pmc
Sep 201719143Highwire
Sep 201761414pmc
Oct 20171895Highwire
Oct 201763131pmc
Nov 20171092Highwire
Nov 201781621pmc
Dec 20174402Highwire
Jan 20181304Highwire
Feb 20186264Highwire
Mar 20183336Highwire
Apr 20186388Highwire
Apr 201831313pmc
May 20182505Highwire
Jun 20186554Highwire
Jun 20182913pmc
Jul 20188363Highwire
Aug 20186467Highwire
Aug 201841313pmc
Sep 20187303Highwire
Oct 20183479Highwire
Nov 20184545Highwire
Dec 201811537Highwire
Jan 20193273Highwire
Feb 20197418Highwire
Mar 201934612Highwire
Apr 201912515Highwire
May 2019124811Highwire
Jun 2019113417Highwire
Jul 20195209Highwire
Aug 20191038210Highwire
Sep 20192167Highwire
Oct 201916399Highwire
Nov 201974010Highwire
Dec 2019123817Highwire
Jan 202043518Highwire
Feb 202063524Highwire
Mar 2020162923Highwire
Apr 20207286Highwire
May 202012012Highwire
Jun 20205278Highwire
Jul 20202248Highwire
Aug 202032213Highwire
Sep 2020619410Highwire
Oct 2020168632Highwire
Nov 2020122620Highwire
Dec 202062512Highwire
Jan 202151822Highwire
Feb 202152011Highwire
Mar 2021142920Highwire
Apr 2021162717Highwire
May 202183423Highwire
Jun 2021517526Highwire
Jul 20214217Highwire
Aug 202174515Highwire
Sep 202142416Highwire
Oct 202153936Highwire
Nov 202191823Highwire
Dec 202132813Highwire
Jan 202242910Highwire
Feb 202221913Highwire
Mar 202272617Highwire
Apr 202252513Highwire
May 202252415Highwire
Jun 202292213Highwire
Jul 20225208Highwire
Aug 202211239Highwire
Sep 202253218Highwire
Oct 202273413Highwire
Nov 202277022Highwire
Dec 202242416Highwire
Jan 202363916Highwire
Feb 2023113212Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles